1S1 Stock Overview
A biotechnology company, discover and develops treatments for serious and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.00 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$10.20 |
| Beta | 1.06 |
| 1 Month Change | -9.77% |
| 3 Month Change | -23.08% |
| 1 Year Change | -52.00% |
| 3 Year Change | -21.05% |
| 5 Year Change | -60.84% |
| Change since IPO | -93.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1S1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.1% | -1.4% | -2.3% |
| 1Y | -52.0% | -23.0% | 1.0% |
Return vs Industry: 1S1 underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 1S1 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 1S1 volatility | |
|---|---|
| 1S1 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 4.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1S1's share price has been volatile over the past 3 months.
Volatility Over Time: 1S1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 94 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| 1S1 fundamental statistics | |
|---|---|
| Market cap | €784.13m |
| Earnings (TTM) | -€203.79m |
| Revenue (TTM) | €269.08k |
2,757x
P/S Ratio-3.6x
P/E RatioIs 1S1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1S1 income statement (TTM) | |
|---|---|
| Revenue | US$288.00k |
| Cost of Revenue | US$149.97m |
| Gross Profit | -US$149.68m |
| Other Expenses | US$68.44m |
| Earnings | -US$218.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | -51,972.57% |
| Net Profit Margin | -75,737.85% |
| Debt/Equity Ratio | 3.5% |
How did 1S1 perform over the long term?
See historical performance and comparison